We have found that the newly developed IRE1-alpha inhibitor small molecule MKC8866 has potent anti-prostate cancer activity. We have also shown that the mechanism of action for MKC8866 is via inhibition of c-MYC oncoprotein expression, the first time ER stress activation was linked to oncogene activation. Our study is now published in Nature Communications. It also attracted attention in national and international media.